DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0003490 A1 Nijhawan (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0003490 A1 Nijhawan (43) Pub US 2007OOO3490A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0003490 A1 Nijhawan (43) Pub. Date: Jan. 4, 2007 (54) MEDICATED GUMSTICK FOR TREATMENT (22) Filed: Jun. 29, 2005 IN ANTI-NFLAMMLATORY CONDITIONS AND PROPHYLAXIS AGAINST NSAID Publication Classification GASTROPATHY (51) Int. Cl. (75) Inventor: Pardeep Nijhawan, Richmond Hill A6IR 9/68 (2006.01) (CA) (52) U.S. Cl. ................................................................ 424/48 Correspondence Address: (57) ABSTRACT IVOR M. HUGHES, BARRISTER & A Stick of gum is provided containing therapeutic benefits of SOLICITOR, non-steroid anti-inflammatory drugs for inflammation in PATENT & TRADEMARKAGENTS conditions such as arthritis, and also alleviates Subsequent 175 COMMERCE VALLEY DRIVE WEST side effects of NSAID administration, as well as antacid SUTE 200 effects from compounds such as an H2 antagonist (raniti THORNHILL, ON L3T 7P6 (CA) dine, cimetidine, famotidine) and/or a proton pump inhibitor (such as lansoprazole, pantoprazole, omeprazole, esomepra (73) Assignee: MEDICAL FUTURES INC. Zole or rabeprazole) and/or an acid pump antagonist selected from the group of Soraprazan, AZD0865, YH1885 and (21) Appl. No.: 11/168,526 CS-526. Patent Application Publication Jan. 4, 2007 Sheet 1 of 2 US 2007/0003490 A1 FIGURE 1 Calcium, Flavouring layer 12 11 Patent Application Publication Jan. 4, 2007 Sheet 2 of 2 US 2007/0003490 A1 FIGURE 2 13 YY N 11 12 US 2007/0003490 A1 Jan. 4, 2007 MEDCATED GUMISTICK FOR TREATMENT IN likely to use NSAIDs and also other medications. These ANTI-NFLAMMATORY CONDITIONS AND medications can lead to an increase in the incidence of pill PROPHYLAXIS AGAINST NSAID GASTROPATHY induced esophagitis. Once again, this can be prevented by using a GPA when ingesting pills. FIELD OF THE INVENTION 0007. These complications formed the basis for intensive 0001. The present invention provides a composition research on the inflammatory state, and it was in the early capable of eliminating or reducing the undesirable side 1990s that a solution to this problem presented itself with the effects resulting from NSAID administration. This compo identification of two structurally related cyclo-oxygenase sition is formulated as a stick chewing gum for convenience isoforms. Labelled COX-1 and COX-2, it was the COX-2 and ease of use. isoform that was identified as the principal isoform involved in inflammation. This concept led to the development and BACKGROUND OF THE INVENTION clinical introduction of COX-2-specific NSAIDs, drugs 0002 The efficacy of non-steroidal antiinflammatories noted for their reduced GI toxicity. (NSAIDs) for treatment of pain, inflammation and fever, has 0008 Unfortunately, after a decade of use, retrospective made these drugs the most commonly used in the world. analysis confirmed the incidence of increased cardiac tox Unfortunately, this class has been limited by their gas icities associated with long term use of COX-2 NSAIDs. trointestinal (GI) toxicity, a side effect that has caused This realization has recently prompted a return to the use of numerous problems. These complications can include dys traditional non-selective NSAIDs for treatment of inflam pepsia, GI upset, gastric ulceration, gastric erosion, duode mation. With this return a rise in the occurrence of NSAID nal ulceration and esophagitis. NSAID gastropathy affects GI complications is anticipated. millions of people annually and results in increased hospi talizations and deaths due to complications from gas 0009. In light of the clinical failure of the COX-2 selec troduodenal bleeds. Furthermore, the incidence of dyspepsia tive NSAIDs for long-term treatment of inflammatory con has been reported to be at 15% in patients taking either ditions, there is a need once again for the relief provided by NSAIDs or COX-2 inhibitors. These patients require addi traditional NSAID therapy. At the same time there is a dire tional medications, such as gastroprotective agents to help need for treatment of the aforesaid harmful side effects reduce the incidence of dyspepsia. arising from NSAID therapy. This urgent and long felt need 0003) In addition, NSAID induced gastropathy can affect has been met with the present invention. up to 80% of all patients who use NSAIDs chronically. Even in those patients using NSAIDs for the short term, gastr PRIOR ART opathy can begin within 72 hours of ingestion of the first 0010 Within the prior art there are several compositions dose of the medication, leading to gastric mucosa damage. formulated including tablets and also chewing gum formu In some cases, patients will arrive at the emergency room lations. All of these fail to address the unique benefits with massive upper gastrointestinal tract bleeds that may be achieved by the present invention. life-threatening. In fact, gastrointestinal complications from 0011. The prior art includes U.S. Pat. No. 5,037,815 by NSAIDs are the most common single side effect of any class Lukacsko et al, wherein NSAIDs are combined with a of drugs in America today. different group of gastroprotective agents, including H2 0004. In patients who do develop gastrointestinal bleed antagonists. This patent outlines how an NSAID and H2 ing from use of NSAIDs, urgent endoscopy and therapy with antagonists can be combined in a tablet formulation. How a group of drugs known as proton pump inhibitors (PPI) is ever, it does not include a gum formulation for increased required. Proton pump inhibitors include lanSoprazole, pan salivation and increased buccal mucosa absorption for toprazole, omeprazole, esomeprazole and rabeprazole. improved treatment of migraine headaches. These drugs have replaced the older histamine receptor 0012 U.S. Pat. No. 6,537,525 describes a chewing gum blockers as the new gastrointestinal protective agent of composition useful for treatment for gastroesophageal reflux choice, although H2 antagonists still play a major role in disease. The composition is taught to include at least one prevention of NSAID gastropathy. PPI are useful for treating ingredient from the group consisting of an acid neutralizing active ulcers, decreasing the incidence of recurrence of agent, and anti-gas agent, and an acid production inhibitor. ulcers, decreasing gastric and esophageal inflammation and Acid production inhibitors include H2 receptor antagonists decreasing the incidence of gastrointestinal bleeding. PPIs and PPIs, as taught within this patent. Examples of H2 and H2 antagonists are collectively referred to as gastropro receptor antagonists are listed as cimetidine, ranitidine and tective agents (GPA). famotidine. Examples of PPIs are listed as lansoprazole and 0005 NSAID induced gastropathy can affect all patients omeprazole. However, the advantage of these agents com including otherwise young and health adults. However, of bined with an NSAID for delivery with the chewing gum the great number of patients requiring NSAID therapy, composition is not contemplated, nor are the benefits taught certain groups are at increased risk of developing the GI of a distinct separation of active ingredients within the complications. These groups include those of advanced age chewing gum. The stick of gum of the present invention is and co morbid conditions such as significant heart disease or unique in that it aims primarily to relieve inflammatory rheumatoid arthritis. Unfortunately, it is in these groups that conditions using an NSAID, while simultaneously amelio relief of inflammatory conditions would be most desired and rating consequences of Such a therapeutic regimen through appreciated. the inclusion of GPAs. 0006 Adding to these increased complications, there is 0013 U.S. Pat. No. 6,773,716 relates to a chewing gum Suggestion from several reports that as we age, we are more product containing a medicament in the coating. The medi US 2007/0003490 A1 Jan. 4, 2007 cament is selected from a group consisting of antacids and approach. The present invention has met this need with a soft anti-inflammatories, including famotidine and omeprazol. chewing gum formulated delivered as a soft stick. and indomethacin and ibuprofen. The present invention addresses the need for a chewing gum Stick which allows for 0018. However, in spite of the general discussions in the ease of use (as opposed to blister packs) in the affected above-mentioned patent literature there is no discussion of arthritic population while provided enhanced absorption the problems facing the elderly in handling blister packages through the buccal mucosa from a larger Surface area. or the like. Blister packages require a certain amount of Furthermore, the immediate invention does not formulate a strength and effort potentially beyond patients Suffering medicament in the coating, but rather is unique in the from arthritis in the joints. The manual dexterity required to placement and separation of active ingredients in the chew open and consume such packaging can be an inhibiting ing gum Stick, designed to enhance stability. factor for those in dire need of the required medicaments. 0014 WO 2004/004478 teaches a compressed chewing 0019. It is therefore a primary object of this invention to gum tablet, and sets out methods for encapsulating the provide a stick gum based pharmaceutical which is easy to chewing gum centre fully or partly with a barrier layer. The art teaches methods of layering gum tablets outlined in the SC. disclosure, along with an improved method for obtaining a 0020. It is a further object of this invention to provide the barrier layer. This barrier layer is taught to protect the gum Stick gum based product which includes two separate com centre during manufacture. Although this patent application ponents separated by an enteric layer. contemplates different pharmaceutical ingredients including acetaminophen, ibuprofen, and indomethacin, along with 0021. It is a further object of this invention to provide the other NSAIDs, ranitidine and other H2 agonists, and lanso stick gum based product which includes an NSAID com prazole and other PPIs, these are formulated in a tablet. The ponent and a PPI component or H2 antagonist component present invention is formulated to provide enhanced absorp separated by an enteric layer.
Load more

Recommended publications
  • Solid Solution Compositions and Use in Chronic Inflammation
    (19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62.
    [Show full text]
  • Use of Aspirin and Nsaids to Prevent Colorectal Cancer
    Evidence Synthesis Number 45 Use of Aspirin and NSAIDs to Prevent Colorectal Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-02-0021 Prepared by: University of Ottawa Evidence-based Practice Center at The University of Ottawa, Ottawa Canada David Moher, PhD Director Investigators Alaa Rostom, MD, MSc, FRCPC Catherine Dube, MD, MSc, FRCPC Gabriela Lewin, MD Alexander Tsertsvadze, MD Msc Nicholas Barrowman, PhD Catherine Code, MD, FRCPC Margaret Sampson, MILS David Moher, PhD AHRQ Publication No. 07-0596-EF-1 March 2007 This report is based on research conducted by the University of Ottawa Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0021). Funding was provided by the Centers for Disease Control and Prevention. The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.
    [Show full text]
  • Horsemen's Information 2016和文TGP 1 薬物修正後 E
    [Conditions] 1 Date December 29 (Tue), 2020 2020 Oi Racetrack, Race 10 2 Location TCK, Oi Racetrack 3 Race The 66th Running of Tokyo Daishoten (GI) 4 Eligibility Thoroughbreds, 3 years old & up 5 Full Gate 16 horses 6 Foreign Runners Selected by the selection committee from among the pre-entered horses. 7 Distance 2,000m, 1 1/4 mile (Right-handed, dirt course) 8 Weight 3 years old: 121.5 lbs,4 years old & up: 125.5 lbs, Female: 4.4 lbs less For 3 year-old-horses from the southern hemisphere, reduce 4.4 lbs from the above weight. 9 Purse Unit: 1,000 JPY Prize Purse & Bonus money Running Record 1st place 6th place allowances prize *1 prize *2 1st place 2nd place 3rd place 4th place 5th place or lower Owner 80,000 28,000 16,000 8,000 4,000 300 300 50 1,600 Trainer 880 70 60 50 40 30 30 80 Jockey 120 110 100 80 70 60 30 80 Groom 80 70 60 50 40 30 30 80 Rider 30 30 80 *1 Paid for the runner who broke the previous record and also set the best record during the race. *2 Prize equivalent to the amount listed in the table above is presented. *3 1 USD= 105.88 JPY (As of August,2020) 10 Handling of Late Scratch No allowance is paid in the case of a late scratch (including cancelation of race due to standstill in a starting gate) approved by TCK, Stewards, and Starter. However, if the chairman of the race meeting operation committee deems that the horse is involved in an accident not caused by the horse, the owner is given an running allowance.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,084,769 B2 Alex Et Al
    US009084769B2 (12) United States Patent (10) Patent No.: US 9,084,769 B2 Alex et al. (45) Date of Patent: Jul. 21, 2015 (54) COMPOSITIONS COMPRISING NON (2013.01); A61K31/192 (2013.01); A61 K STEROIDAL ANTI-INFLAMMLATORY DRUGS 31/415 (2013.01); A61 K3I/7016 (2013.01) AND METHODS FOR USE THEREOF (58) Field of Classification Search CPC A61K 2300/00; A61K 31/7016; A61K 33/30 (71) Applicants:Phillip Alex, Abingdon, MD (US); Ben USPC .................................. 424/641, 451, 474, 490 Johns, Scotch Plains, NJ (US) See application file for complete search history. (72) Inventors: Phillip Alex, Abingdon, MD (US); Ben (56) References Cited Johns, Scotch Plains, NJ (US) |U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 2010/0150861 A1* 6/2010 Geibel et al. ................. 424/85.2 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/705,552 Watanabe et al. Prebiotic Properties of Epilactose. Aug. 5, 2008. J. Dairy Sci. pp. 4518-4526.” (22) Filed: Dec. 5, 2012 Lanza et al. NSAID-induced gastric ulceration is dose related by weight: an endoscopic study with flurbiprofen. May 1993. Am J (65) Prior Publication Data Gastroenterol. Abstract.” |US 2013/0142869 A1 Jun. 6, 2013 * cited by examiner Primary Examiner – Frederick Krass Related U.S. Application Data Assistant Examiner – Tracy Liu (60) Provisional application No. 61/566,765, filed on Dec. (74) Attorney, Agent, or Firm – Christina Chamberlin 5, 2011. (57) ABSTRACT (51) Int. Cl. The invention provides analgesic, antipyretic and anti-in A6 IK 3.1/7016 (2006.01) flammatory compositions containing epilactose in combina A6 IK 33/30 (2006.01) tion with non-steroidal anti-inflammatory drugs and pharma A6 IK 31/167 (2006.01) ceutically acceptable zinc compounds.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Drugs for Dysmenorrhoea (Review)
    Cochrane Database of Systematic Reviews Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001751. DOI: 10.1002/14651858.CD001751.pub3. www.cochranelibrary.com Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 Figure1. ..................................... 8 Figure2. ..................................... 10 Figure3. ..................................... 12 RESULTS....................................... 14 Figure4. ..................................... 16 Figure5. ..................................... 18 Figure6. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 25 DISCUSSION ..................................... 26 AUTHORS’CONCLUSIONS . 27 ACKNOWLEDGEMENTS . 27 REFERENCES ..................................... 28 CHARACTERISTICSOFSTUDIES . 40 DATAANDANALYSES. 130 Analysis 1.1. Comparison 1 NSAIDs vs placebo, Outcome 1 Pain relief dichotomous data. 136
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,955,097 Tapolsky Et Al
    USOO595.5097A United States Patent (19) 11 Patent Number: 5,955,097 Tapolsky et al. (45) Date of Patent: Sep. 21, 1999 54 PHARMACEUTICAL PREPARATION 4,894,232 1/1990 Reul et al. .............................. 424/439 APPLICABLE TO MUCOSAL SURFACES 4,900,554 2/1990 Yanagibashi et al. 424/448 AND BODY TISSUES 4,906.463 3/1990 Cleary et al. ....... ... 424/78 4.915,948 4/1990 Gallopo et al. ......................... 424/435 5,059,189 10/1991 Cilento et al. .......................... 604/307 Inventors: Gilles H. Tapolsky; David W. 5,081,157 1/1992 Pomerantz ... 514/781 Osborne, both of The Woodlands, Tex. 5,081,158 1/1992 Pomerantz 514/781 5,137,729 8/1992 Kuroya et al.. Assignee: Virotex Corporation, Ft. Collins, Colo. 5,166,233 11/1992 Takamasa et al. 5,192,802 3/1993 Rencher .................................. 514/535 Appl. No.: 08/733,454 5,298.258 3/1994 Akemi et al.. 5,314.915 5/1994 Rencher .................................. 514/535 Filed: Oct. 18, 1996 5,462,749 10/1995 Rencher ... ... 424/484 Int. Cl." ............................. A61F 13/00; A61K 9/14 5,540,930 7/1996 Guy et al. ............................... 424/434 U.S. Cl. ............................................. 424/434; 424/486 FOREIGN PATENT DOCUMENTS Field of Search ...................................... 424/434, 486 56-100714 8/1981 Japan. References Cited Primary Examiner Bernard Lipman ASSistant Examiner N. Sarofim U.S. PATENT DOCUMENTS Attorney, Agent, or Firm Morrison & Foerster LLP 3.257.276 6/1966 Broh-Kahn et al.. 57 ABSTRACT 3,640,741 2/1972 Etes ......................................... 106/170 3.996,934 12/1976 Zaffaroni. The present invention relates to a non water-Soluble phar 4,226,848 10/1980 Nagai et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]